Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma: Expert Perspectives on Treatment Advances

Sagar Lonial, MD, of Emory University School of Medicine, and Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discuss the top presentations on multiple myeloma delivered at this year’s meeting.

Bladder Cancer

Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss mutation burden—its role in response to treatment with PD-L1 immunotherapy and its impact on progression-free survival and overall survival, as well as the link between intrinsic expression subtypes and treatment outcome with atezolizumab (Abstract 104).

Global Cancer Care

Eduardo L. Cazap, MD, PhD, and Mary Gospodarowicz, MD, on The South American Perspective of Cancer Research

Eduardo L. Cazap, MD, PhD, of the Latinamerican & Caribbean Society of Medical Oncology, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.

Breast Cancer

Lisa A. Carey, MD, and Nicholas C. Turner, MD, PhD, on PALOMA-2 and -3 Study Findings in Advanced Breast Cancer

Lisa A. Carey, MD, of the University of North Carolina, and Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital and Institute of Cancer Research, discuss the efficacy of palbociclib plus fulvestrant in patients with ESR1 mutations in circulating tumor DNA, and palbociclib and letrozole for postmenopausal women with ER+/HER2–advanced breast cancer (Abstracts 507, 524).

Gynecologic Cancers

Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial

Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).

Jan

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma: Expert Perspectives on Treatment Advances

Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab

Eduardo L. Cazap, MD, PhD, and Mary Gospodarowicz, MD, on The South American Perspective of Cancer Research

Lisa A. Carey, MD, and Nicholas C. Turner, MD, PhD, on PALOMA-2 and -3 Study Findings in Advanced Breast Cancer

Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial

ChatGPT Has Limitations in Clinical Utility for Colorectal Cancer but May Be Useful for Patient Education

Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors

Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk

ASCO Thanks Drs Bertagnolli Rathmell for Their Service Leading NIH NCI

New Study Identifies Potential Dose Dependent Relationship Among Alcohol Consumption HBV Associated Cirrhosis Hepatocellular Carcinoma